Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Obesity is a complex metabolic disease requiring effective pharmacotherapies.
• Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant efficacy in weight management.
• Understanding tirzepatide's effectiveness based on patient characteristics and prior treatment is crucial for optimizing clinical use.

Purpose of the Study:

• To compare weight-loss outcomes in patients prescribed tirzepatide based on their prior weight-loss status.
• To assess tirzepatide's efficacy in patients transitioning from semaglutide therapy.
• To analyze weight-loss results stratified by type 2 diabetes (T2D) status and reasons for switching from semaglutide.

Main Methods:

• Retrospective cohort study analyzing 6-month weight-loss outcomes in adults treated with tirzepatide (May 2022-January 2023).
• Patients were categorized as 'weight-reduced' (≥10% total body weight loss prior to tirzepatide) or 'non-weight-reduced'.
• Analysis included patients switching from semaglutide, with reasons for switching (non-response, plateau) documented.

Main Results:

• Of 293 patients meeting criteria, 133 were pre-weight-reduced and 160 were not.
• Non-weight-reduced patients achieved greater weight loss (10.3% TBW) compared to weight-reduced patients (7.2% TBW; p<0.001).
• Patients switching from semaglutide due to plateau (8.1% TBW loss) had better outcomes than non-responders (2.9% TBW loss; p<0.001).

Conclusions:

• Tirzepatide demonstrates significant weight-loss efficacy across different patient profiles.
• Prior weight-loss status and response to semaglutide influence tirzepatide outcomes.
• Tirzepatide offers a valuable therapeutic option for weight management, with outcomes varying by individual patient factors.